Causes or Cures Mayo Clinic Test Predicts Who Gets GLP-1 Side Effects, with Dr. Andres Acosta
Dr. Acosta returns to Causes or Cures to talk about the next big leap in obesity research: using genetics and machine learning to predict which patients will get side effects to popular GLP-1 weight-loss medications like Wegovy and Zepbound. Previously, he was on Causes or Cures to discuss your individual obesity type.
He and his team are uncovering why some people experience major weight loss while others face tough side effects—especially nausea. The goal? True precision medicine for obesity: matching the right treatment to the right person before treatment even begins. (You can learn more about their available tests and company here.)
Topics We Discuss
- Dr. Acosta’s background and what drew him to obesity research
- Why not all obesity is the same—and why that matters for patients and doctors
- The most common questions patients ask about GLP-1 drugs like Wegovy and Zepbound
- How big a problem side effects like nausea really are in practice
- New research using genetic markers to predict who’s more likely to experience side effects
- Whether eating style affects nausea and how Dr. Acosta coaches patients on nutrition while using these medications
- The possibility of genetic testing before prescribing GLP-1s
- What we know about rarer side effects, from vision to hearing changes, if he thinks more side effects will emerge
- What “satiation” (feeling full) means and why it varies so much between people
- How genetic risk and satiation scores could determine which obesity treatment works best
- Dr. Acosta's thoughts on obesity prevention, especially on renewed energy to take on the unhealthy food industry
- The persistence of stigma—why “willpower” doesn’t tell the whole story
- Whether the current obsession with obesity drugs distracts from prevention, nutrition, and community health
Listen if you’ve ever wondered:
- Why GLP-1 drugs don’t work the same for everyone
- What your genes have to do with weight loss, feeling full and side effects
- How soon doctors could use genetic tests to personalize obesity treatment
- Whether prevention is being overshadowed by the pharma spotlight
Why it matters
Obesity isn’t a one-size-fits-all condition—and neither should its treatment be. Dr. Acosta’s research could mark a turning point in how we approach weight loss: scientifically, compassionately, and individually.
Dr. Acosta is a Consultant of Gastroenterology and Hepatology at the Mayo Clinic, co-founder of Phenomix Sciences, as well as an Associate Professor of Medicine. His research focus is on gastrointestinal physiology and the complexity of food intake regulation as it relates to obesity. You can learn more about his work here.
You can contact Dr. Eeks at bloomingwellness.com.
Follow Eeks on Instagram here.
Or Facebook here.
Or X.
On Youtube.
Or TikTok.
SUBSCRIBE to her WEEKLY newsletter here! (Now featuring interviews with top experts on health you care about!)